MRI-based Zero Echo Time and Black Bone Pseudo-CT Compared with Whole-Body CT to Detect Osteolytic Lesions in Multiple Myeloma.


Journal

Radiology
ISSN: 1527-1315
Titre abrégé: Radiology
Pays: United States
ID NLM: 0401260

Informations de publication

Date de publication:
Oct 2024
Historique:
medline: 8 10 2024
pubmed: 8 10 2024
entrez: 8 10 2024
Statut: ppublish

Résumé

Background MRI is highly sensitive for assessing bone marrow involvement in multiple myeloma (MM) but does not enable detection of osteolysis. Purpose To assess the diagnostic accuracy, repeatability, and reproducibility of pseudo-CT MRI sequences (zero echo time [ZTE], gradient-echo black bone [BB]) in detecting osteolytic lesions in MM using whole-body CT as the reference standard. Materials and Methods In this prospective study, consecutive patients were enrolled in our academic hospital between June 2021 and December 2022. Inclusion criteria were newly diagnosed MM, monoclonal gammopathy of undetermined significance at high risk for MM, or suspicion of progressive MM. Participants underwent ZTE and BB sequences covering the lumbar spine, pelvis, and proximal femurs as part of 3-T whole-body MRI examinations, as well as clinically indicated fluorine 18 fluorodeoxyglucose PET/CT examination within 1 month that included optimized whole-body CT. Ten bone regions and two scores (categorical score = presence/absence of osteolytic lesion; semiquantitative score = osteolytic lesion count) were assessed by three radiologists (two experienced and one unfamiliar with pseudo-CT reading) on the ZTE, BB, and whole-body CT images. The accuracy, repeatability, and reproducibility of categorical scores (according to Gwet agreement coefficients AC1 and AC2) and differences in semiquantitative scores were assessed at the per-sequence, per-region, and per-patient levels. Results A total of 47 participants (mean age, 67 years ± 11 [SD]; 27 male) were included. In experienced readers, BB and ZTE had the same high accuracy (98%) in the per-patient analysis, while BB accuracy ranged 83%-100% and ZTE accuracy ranged 74%-94% in the per-region analysis. An increase of false-negative (FN) findings in the spine ranging from +17% up to +23%, according to the lumbar vertebra, was observed using ZTE (

Identifiants

pubmed: 39377681
doi: 10.1148/radiol.231817
doi:

Banques de données

ClinicalTrials.gov
['NCT05381077']

Types de publication

Journal Article Comparative Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e231817

Auteurs

Frederic E Lecouvet (FE)

From the Departments of Medical Imaging (F.E.L., D.Z., C.C., P.T., T.K., L.T., N.M.), Hematology (M.C.V.), and Nuclear Medicine (O.G.), Institut de Recherche Expérimentale et Clinique (IREC), Institut du Cancer Roi Albert II, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels, Avenue Hippocrate 10, B-1200 Brussels, Belgium; Department of Medical Imaging, Hôpitaux Universitaires de Genève, Geneva, Switzerland (D.L.); GE HealthCare, Diegem, Belgium (G.D.); Department of Medical Imaging, CHU Saint Pierre, Brussels, Belgium (O.C.); and GE HealthCare, Buc, France (J.P.).

Deniz Zan (D)

From the Departments of Medical Imaging (F.E.L., D.Z., C.C., P.T., T.K., L.T., N.M.), Hematology (M.C.V.), and Nuclear Medicine (O.G.), Institut de Recherche Expérimentale et Clinique (IREC), Institut du Cancer Roi Albert II, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels, Avenue Hippocrate 10, B-1200 Brussels, Belgium; Department of Medical Imaging, Hôpitaux Universitaires de Genève, Geneva, Switzerland (D.L.); GE HealthCare, Diegem, Belgium (G.D.); Department of Medical Imaging, CHU Saint Pierre, Brussels, Belgium (O.C.); and GE HealthCare, Buc, France (J.P.).

Darius Lepot (D)

From the Departments of Medical Imaging (F.E.L., D.Z., C.C., P.T., T.K., L.T., N.M.), Hematology (M.C.V.), and Nuclear Medicine (O.G.), Institut de Recherche Expérimentale et Clinique (IREC), Institut du Cancer Roi Albert II, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels, Avenue Hippocrate 10, B-1200 Brussels, Belgium; Department of Medical Imaging, Hôpitaux Universitaires de Genève, Geneva, Switzerland (D.L.); GE HealthCare, Diegem, Belgium (G.D.); Department of Medical Imaging, CHU Saint Pierre, Brussels, Belgium (O.C.); and GE HealthCare, Buc, France (J.P.).

Caroline Chabot (C)

From the Departments of Medical Imaging (F.E.L., D.Z., C.C., P.T., T.K., L.T., N.M.), Hematology (M.C.V.), and Nuclear Medicine (O.G.), Institut de Recherche Expérimentale et Clinique (IREC), Institut du Cancer Roi Albert II, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels, Avenue Hippocrate 10, B-1200 Brussels, Belgium; Department of Medical Imaging, Hôpitaux Universitaires de Genève, Geneva, Switzerland (D.L.); GE HealthCare, Diegem, Belgium (G.D.); Department of Medical Imaging, CHU Saint Pierre, Brussels, Belgium (O.C.); and GE HealthCare, Buc, France (J.P.).

Marie-Christiane Vekemans (MC)

From the Departments of Medical Imaging (F.E.L., D.Z., C.C., P.T., T.K., L.T., N.M.), Hematology (M.C.V.), and Nuclear Medicine (O.G.), Institut de Recherche Expérimentale et Clinique (IREC), Institut du Cancer Roi Albert II, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels, Avenue Hippocrate 10, B-1200 Brussels, Belgium; Department of Medical Imaging, Hôpitaux Universitaires de Genève, Geneva, Switzerland (D.L.); GE HealthCare, Diegem, Belgium (G.D.); Department of Medical Imaging, CHU Saint Pierre, Brussels, Belgium (O.C.); and GE HealthCare, Buc, France (J.P.).

Gaëtan Duchêne (G)

From the Departments of Medical Imaging (F.E.L., D.Z., C.C., P.T., T.K., L.T., N.M.), Hematology (M.C.V.), and Nuclear Medicine (O.G.), Institut de Recherche Expérimentale et Clinique (IREC), Institut du Cancer Roi Albert II, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels, Avenue Hippocrate 10, B-1200 Brussels, Belgium; Department of Medical Imaging, Hôpitaux Universitaires de Genève, Geneva, Switzerland (D.L.); GE HealthCare, Diegem, Belgium (G.D.); Department of Medical Imaging, CHU Saint Pierre, Brussels, Belgium (O.C.); and GE HealthCare, Buc, France (J.P.).

Ophélye Chiabai (O)

From the Departments of Medical Imaging (F.E.L., D.Z., C.C., P.T., T.K., L.T., N.M.), Hematology (M.C.V.), and Nuclear Medicine (O.G.), Institut de Recherche Expérimentale et Clinique (IREC), Institut du Cancer Roi Albert II, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels, Avenue Hippocrate 10, B-1200 Brussels, Belgium; Department of Medical Imaging, Hôpitaux Universitaires de Genève, Geneva, Switzerland (D.L.); GE HealthCare, Diegem, Belgium (G.D.); Department of Medical Imaging, CHU Saint Pierre, Brussels, Belgium (O.C.); and GE HealthCare, Buc, France (J.P.).

Perrine Triqueneaux (P)

From the Departments of Medical Imaging (F.E.L., D.Z., C.C., P.T., T.K., L.T., N.M.), Hematology (M.C.V.), and Nuclear Medicine (O.G.), Institut de Recherche Expérimentale et Clinique (IREC), Institut du Cancer Roi Albert II, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels, Avenue Hippocrate 10, B-1200 Brussels, Belgium; Department of Medical Imaging, Hôpitaux Universitaires de Genève, Geneva, Switzerland (D.L.); GE HealthCare, Diegem, Belgium (G.D.); Department of Medical Imaging, CHU Saint Pierre, Brussels, Belgium (O.C.); and GE HealthCare, Buc, France (J.P.).

Thomas Kirchgesner (T)

From the Departments of Medical Imaging (F.E.L., D.Z., C.C., P.T., T.K., L.T., N.M.), Hematology (M.C.V.), and Nuclear Medicine (O.G.), Institut de Recherche Expérimentale et Clinique (IREC), Institut du Cancer Roi Albert II, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels, Avenue Hippocrate 10, B-1200 Brussels, Belgium; Department of Medical Imaging, Hôpitaux Universitaires de Genève, Geneva, Switzerland (D.L.); GE HealthCare, Diegem, Belgium (G.D.); Department of Medical Imaging, CHU Saint Pierre, Brussels, Belgium (O.C.); and GE HealthCare, Buc, France (J.P.).

Lokmane Taihi (L)

From the Departments of Medical Imaging (F.E.L., D.Z., C.C., P.T., T.K., L.T., N.M.), Hematology (M.C.V.), and Nuclear Medicine (O.G.), Institut de Recherche Expérimentale et Clinique (IREC), Institut du Cancer Roi Albert II, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels, Avenue Hippocrate 10, B-1200 Brussels, Belgium; Department of Medical Imaging, Hôpitaux Universitaires de Genève, Geneva, Switzerland (D.L.); GE HealthCare, Diegem, Belgium (G.D.); Department of Medical Imaging, CHU Saint Pierre, Brussels, Belgium (O.C.); and GE HealthCare, Buc, France (J.P.).

Julie Poujol (J)

From the Departments of Medical Imaging (F.E.L., D.Z., C.C., P.T., T.K., L.T., N.M.), Hematology (M.C.V.), and Nuclear Medicine (O.G.), Institut de Recherche Expérimentale et Clinique (IREC), Institut du Cancer Roi Albert II, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels, Avenue Hippocrate 10, B-1200 Brussels, Belgium; Department of Medical Imaging, Hôpitaux Universitaires de Genève, Geneva, Switzerland (D.L.); GE HealthCare, Diegem, Belgium (G.D.); Department of Medical Imaging, CHU Saint Pierre, Brussels, Belgium (O.C.); and GE HealthCare, Buc, France (J.P.).

Olivier Gheysens (O)

From the Departments of Medical Imaging (F.E.L., D.Z., C.C., P.T., T.K., L.T., N.M.), Hematology (M.C.V.), and Nuclear Medicine (O.G.), Institut de Recherche Expérimentale et Clinique (IREC), Institut du Cancer Roi Albert II, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels, Avenue Hippocrate 10, B-1200 Brussels, Belgium; Department of Medical Imaging, Hôpitaux Universitaires de Genève, Geneva, Switzerland (D.L.); GE HealthCare, Diegem, Belgium (G.D.); Department of Medical Imaging, CHU Saint Pierre, Brussels, Belgium (O.C.); and GE HealthCare, Buc, France (J.P.).

Nicolas Michoux (N)

From the Departments of Medical Imaging (F.E.L., D.Z., C.C., P.T., T.K., L.T., N.M.), Hematology (M.C.V.), and Nuclear Medicine (O.G.), Institut de Recherche Expérimentale et Clinique (IREC), Institut du Cancer Roi Albert II, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels, Avenue Hippocrate 10, B-1200 Brussels, Belgium; Department of Medical Imaging, Hôpitaux Universitaires de Genève, Geneva, Switzerland (D.L.); GE HealthCare, Diegem, Belgium (G.D.); Department of Medical Imaging, CHU Saint Pierre, Brussels, Belgium (O.C.); and GE HealthCare, Buc, France (J.P.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH